A hormone therapy for breast cancer can reduce the chances of deadly spread of the disease by nearly a fifth, according to new trial findings. Women given the aromatase inhibitor exemestane after surgery were 19% less likely to suffer metastatic, or spreading, cancer than those receiving standard treatment. Cancer is most deadly when it travels around the body, affecting vital organs such as the brain or liver. Each year more than 45,600 new cases of breast cancer are diagnosed in the UK and the disease kills around 12,300 women. Exemestane, marketed as Aromasin, works by shutting off production of the...